TABLE 8.

Summary of treatment-emergent adverse events.

Parameter	Fasting conditions			Postprandial conditions
	T	R	Total	T	R	Total
No. of subjects dosed	36	36	—	71	72	—
No. (%) of subjects with at least 1 TEAE	6 (16.7)	6 (16.7)	10 (27.8)	10 (14.1)	10 (13.9)	19 (26.4)
No. of TEAEs	6	11	17	14	23	37
Grade 1	5	7	12	11	17	28
Grade 2	1	4	5	2	5	7
≥Grade 3	0	0	0	1	1	2
No. of subjects discontinued due to TEAE	0	0	0	1	0	1
Adverse event [no. (%) of subjects, no. of AEs]	—	—	—	—	—	—
Hypertriglyceridemia	3 (8.3) 3	1 (2.8) 1	—	3 (4.2) 3	4 (5.6) 4	—
Hyperkalemia	0 (0) 0	0 (0) 0	—	1 (1.4) 1	0 (0) 0	—
Monocytopenia	0 (0) 0	0 (0) 0	—	2 (2.8) 2	0 (0) 0	—
Eosinophil count increased	0 (0) 0	0 (0) 0	—	0 (0) 0	4 (5.6) 4	—
Proteinuria	0 (0) 0	0 (0) 0	—	2 (2.8) 2	0 (0) 0	—
Positive acetone in the urine	0 (0) 0	0 (0) 0	—	0 (0) 0	1 (1.4) 1	—
Urine leukocytes increased	1 (2.8) 1	1 (2.8) 1	—	0 (0) 0	1 (1.4) 1	—
Alanine aminotransferase increased	0 (0) 0	1 (2.8) 1	—	0 (0) 0	0 (0) 0	—
Blood basophils increased	0 (0) 0	1 (2.8) 1	—	0 (0) 0	0 (0) 0	—
Aspartate aminotransferase increased	0 (0) 0	1 (2.8) 1	—	0 (0) 0	0 (0) 0	—
Blood conjugated bilirubin increased	0 (0) 0	2 (5.6) 2	—	0 (0) 0	2 (2.8) 2	—
Blood unconjugated bilirubin increased	0 (0) 0	1 (2.8) 1	—	1 (1.4) 1	2 (2.8) 2	—
Blood total bilirubin increased	0 (0) 0	1 (2.8) 1	—	1 (1.4) 1	2 (2.8) 2	—
Diarrhea	1 (2.8) 1	1 (2.8) 1	—	0 (0) 0	0 (0) 0	—
Hypertension	1 (2.8) 1	1 (2.8) 1	—	2 (2.8) 2	2 (2.8) 2	—
Rapid pulse	0 (0) 0	0 (0) 0	—	1 (1.4) 2	2 (2.8) 3	—
Upper respiratory tract infection	0 (0) 0	0 (0) 0	—	0 (0) 0	1 (1.4) 1	—
Eczema	0 (0) 0	0 (0) 0	—	0 (0) 0	1 (1.4) 1	—